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ABSTRACT
Introduction: We analyze how infectious disease physicians perceive and manage invasive candidosis in Brazil, in comparison 
to intensive care unit specialists. Methods: A 38-question survey was administered to 56 participants. Questions involved 
clinicians’ perceptions of the epidemiology, diagnosis, treatment and prophylaxis of invasive candidosis. P < 0.05 was considered 
statistically signiﬁ cant. Results: The perception that candidemia not caused by Candida albicans occurs in less than 10% of 
patients is more commonly held by intensive care unit specialists (p=0.018). Infectious disease physicians almost always 
use antifungal drugs in the treatment of patients with candidemia, and antifungal drugs are not as frequently prescribed by 
intensive care unit specialists (p=0.006). Infectious disease physicians often do not use voriconazole when a patient’s antifungal 
treatment has failed with ﬂ uconazole, which also differs from the behavior of intensive care unit specialists (p=0.019). Many 
intensive care unit specialists use ﬂ uconazole to treat candidemia in neutropenic patients previously exposed to ﬂ uconazole, in 
contrast to infectious disease physicians (p=0.024). Infectious disease physicians prefer echinocandins as a ﬁ rst choice in the 
treatment of unstable neutropenic patients more frequently than intensive care unit specialists (p=0.013). When candidemia is 
diagnosed, most infectious disease physicians perform fundoscopy (p=0.015), whereas intensive care unit specialists usually 
perform echocardiograms on all patients (p=0.054). Conclusions: This study reveals a need to better educate physicians in Brazil 
regarding invasive candidosis. The appropriate management of this disease depends on more drug options being available in our 
country in addition to global coverage in private and public hospitals, thereby improving health care.
Keywords:  Candidiasis. Candidemia. Invasive fungal infection. Medical education.
Invasive fungal diseases have markedly increased in 
prevalence in recent decades1. Candidosis is currently 
recognized as one of the leading causes of death in critically ill 
patients. The overall mortality associated with invasive Candida 
infections is nearly 60%, with an attributable mortality as high 
as 40%2. In the USA and in many developed countries, Candida 
spp. have become the fourth leading cause of bloodstream 
infections (BSIs)3. Similar ﬁ ndings have been obtained in 
studies conducted in Brazil1,2. In addition, the costs of modern 
antifungal therapy have turned candidemia into one of the most 
expensive infections in clinical practice4.
Understanding how physicians perceive a particular disease 
is a critical step in establishing priorities for educational 
programs directed at them. We therefore analyzed how 
infectious disease (ID) physicians manage invasive candidosis 
in Brazil, in comparison to intensive care unit (ICU) specialists. 
Only one similar report was found in the literature in which 
management choices by both specialties were compared13.
METHODS
In the present study, we sequentially selected ID and ICU 
physicians working in tertiary care hospitals from three large 
Brazilian cities (Porto Alegre, Curitiba and São Paulo) who 
met the following criteria: I) they were board-certiﬁ ed by their 
respective medical societies; II) they worked in a tertiary care 
hospital with a minimum of 100 beds and at least one ICU; 
III) they had at least 3 years of clinical experience in their 
specialty after ﬁ nishing medical residency; and IV) they had 
treated at least one patient with invasive fungal disease in 
the last year (pneumocystosis not included). Volunteers were 
mostly recruited during scientiﬁ c meetings, during the years 
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2010-2011, and a single researcher applied the 38-topic survey 
to all participants. The study included questions related to the 
clinicians’ perceptions on the epidemiology, diagnosis, treatment 
and prevention of invasive candidosis. Additional questions 
also addressed the institutions’ capability to diagnose invasive 
Candida infections. This article did not require approval of 
the ethics committee because the participants were physicians, 
and any interventions had already been made.  All participants 
freely signed informed consent forms, and their identities 
were kept secret. Data obtained in the survey were contrasted 
with the Infectious Diseases Society of America’s (IDSA) 
recommendations for the treatment of candidemia3, and also with 
previously published epidemiological data from the participating 
centers1,2,5-7.Statistical analyses were performed using SPSS 
version 16.0 for Windows. Categorical variables were compared 
using chi-squared or Fisher’s exact tests, wherever appropriate. 
P < 0.05 was considered statistically signiﬁ cant.
Participating physicians and institutions
In total, 56 clinicians from 19 hospitals were interviewed, 
including 22 ID specialists and 32 ICU physicians. Two 
physicians were certiﬁ ed in both areas and included in both 
groups. All participants worked in large tertiary hospitals 
(median of 700 hospital beds and 33 ICU beds; Table 1). 
Hospitals were public (57.1%), private (17.9%), or mixed 
(25%). Most (92.9%) institutions were teaching hospitals. The 
main ﬁ ndings of this study are summarized in Table 2.
Hospitals’ capabilities for diagnosing 
invasive Candida infections
Automated blood cultures and yeast identification at the 
species level were available for 96.4% and 90.9% of the 
participants, respectively. The lysis-centrifugation system method 
was available for 30.3%, whereas 1-3-β-d-glucan and Candida 
protein chain reaction (PCR) assays were available for 10.7% 
and 36.6%, respectively (with no difference in proportions 
between medical specialties). Antifungal susceptibility tests were 
accessible to 49.1% of the clinicians. The ICU physicians had a 
higher frequency of compulsory requests for susceptibility tests 
when candidemia was diagnosed than ID physicians (62.5% 
vs. 44.4%), but the difference was not statistically signiﬁ cant 
(p=0.434).
Awareness of the epidemiology of 
invasive Candida infections
The distribution of Candida species causing candidemia 
in each medical center was allegedly known by 80% of 
participants. However, 69.6% of the ICU physicians believed 
that the frequency of non-Candida albicans species was lower 
than 10% in their hospitals, in contrast to 31.2% of ID doctors 
(p=0.018). The proportion of C. glabrata infections causing 
candidemia was perceived to be lower than 10% by 90.9% of 
participants, with no difference between specialties.
Do physicians always treat patients with positive blood 
cultures for Candida spp.?
Whereas 95.8% of ID specialists afﬁ rmed that all patients 
with candidemia require antifungal treatment, this proportion 
was only 65.6% among ICU specialists (p=0.006). For ICU 
specialists, absence of sepsis was the main reason for potentially 
not offering antifungal drugs to a patient with candidemia 
(63.6%). Moreover, 45.4% of the ICU physicians who claimed 
not to treat their patients with antifungal drugs also reported not 
asking for routine eye examinations. Fundoscopy was performed 
systematically when treating a patient with candidemia by only 
54.5% of those physicians surveyed (ID 65.2%, ICU 46.9%; 
p=0.178). The proportions of physicians reporting that eye 
examination was never requested were 13% and 43.8% (ID and 
ICU, respectively; p=0.015).
Primary antifungal treatment choices 
for candidemia
Nearly (96.4%) all participants expressed concerns 
regarding ﬂ uconazole use in patients with invasive Candida 
infections. However, ﬂ uconazole was the preferred antifungal 
drug for 91.1% of the interviewed physicians for treating 
non-neutropenic, stable patients with candidemia. For patients 
previously exposed to azoles, ﬂ uconazole remained the drug 
of choice for 46.9% and 12.5% of the ICU and ID physicians, 
respectively (p=0.024). Loading doses of ﬂ uconazole were 
prescribed by only 34.4% and 58.3% of the ICU and ID 
physicians (p=0.074), respectively, and none of the participants 
adjusted the ﬂ uconazole dose based on body weight. Moreover, 
14.3% would consider fluconazole for the treatment of 
candidemia caused by C. glabrata, and 8.9% would use it 
for C. krusei infections, with no differences between medical 
specialties. Voriconazole was considered a reasonable second-
line option in the treatment of patients with candidemia where 
ﬂ uconazole had failed by 42.9% of responders, and 75% of 
these were ICU physicians (p=0.019).
Many (33.9%) physicians would consider ﬂ uconazole as 
the drug of choice in the treatment of unstable patients with 
candidemia (ID 25%, ICU 40.6%; p=0.222). Echinocandins 
were preferred in such scenario by only 33.9% of the individuals 
surveyed (ID 45.8%, ICU 25.0%; p=0.103). The recommended 
caspofungin dosages for patients with candidemia were unknown 
to a quarter of the physicians interviewed, and 71.4% of these 
individuals were ICU physicians. Similarly, anidulafungin 
dosages were unknown to 46.4% of the participants, among 
whom 73% were ICU physicians.
Most (62.5%) ICU physicians were not aware of any limitation 
regarding the use of amphotericin B in C. lusitaniae infections. 
Additionally, 50% of ICU specialists were not able to comment on 
the use of echinocandins for C. parapsilosis or C. guilliermondii 
infections (p<0.001 for all comparisons with ID physicians).
For neutropenic patients with candidemia who were not 
previously exposed to azoles, ﬂ uconazole was the drug of choice 
for 75% of ICU and ID physicians. In the case of an unstable 
neutropenic patient, 46.8% of the ICU physicians preferred 
a polyene, either deoxycholate amphotericin B (31.2%) or a 
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TABLE 2 - The main differences observed between ID and ICU specialists regarding perceptions and management of Candida infections. 
 ID ICU
 doctors doctors P
 (%)  (%) value
Perception that candidemia caused by Candida species other than C. albicans occurred in less than 10% of cases 31.2 69.6 0.018
Treatment of all patients with candidemia with antifungal drugs 95.8 65.6 0.006
Systematic removal of short-term central venous catheters 70.8 93.8 0.030
Use of voriconazole for patients in whom ﬂ uconazole failed 25.0 56.2 0.019
Fluconazole use for neutropenic patients previously exposed to azoles 12.5 46.9 0.024
Lack of knowledge on echinocandin dosage 29.2 68.8 0.003
Echinocandins as ﬁ rst-choice for unstable neutropenic patients 50.0 18.8 0.013
Fundoscopy never performed 13.0 43.8 0.015
Echocardiogram for all patients 16.7 46.6 0.054
ID: infectious disease specialist; ICU: intensive care unit specialist.
lipid formulation of amphotericin B (15.6%). Echinocandins 
were preferred by 50% and 18.8% of ID and ICU physicians, 
respectively, in such a context (p=0.013).
Combining antifungal drugs for the treatment of invasive 
Candida infections was an uncommon practice (10.7%; n=6). 
Most situations in which such practice was considered were in 
episodes of Candida endocarditis (n=3) and meningitis (n=2), 
or in the treatment of neutropenic patients (n=4).
Management of central venous catheters
Systematic removal of short-term management of central 
venous catheters (CVCs) was the usual practice for 93.8% of 
ICU specialists, in contrast to 70.8% of ID physicians (p=0.030). 
Regarding long-term CVCs, these proportions were 51.6% and 
54.2%, respectively.
Frequency of blood culture after 
candidemia diagnosis 
Following the diagnosis of candidemia, most participants 
(58.9%) reported obtaining additional blood cultures at 48-72h 
intervals until the clearance of candidemia was documented. No 
signiﬁ cant differences in this protocol were observed between 
ID and ICU physicians.
Echocardiographic examination
The proportion of physicians who requested an 
echocardiogram for patients with candidemia, persistent fever 
and blood cultures remaining positive for Candida spp. was 
43.8% and 66.7% for ICU and ID physicians, respectively 
(p=0.089). Table1 summarizes the results of the survey.
DISCUSSION
This study reveals that intensive care and infectious 
disease physicians in Brazil differ in several ways on how they 
understand the epidemiology of invasive Candida infections 
and on the clinical management of such conditions. Most 
physicians who were selected to participate in the study were 
based in large tertiary hospitals in which proper diagnostic 
facilities were apparently in place. Moreover, the epidemiology 
of candidemia had been well-documented over the preceding 
years in the medical centers in which these physicians were 
working1,2,5-7. We were surprised to see that, despite enjoying 
these advantages, a large proportion of the physicians who 
were interviewed demonstrated little knowledge regarding the 
epidemiology of invasive Candida infections. For instance, 
more than half of the participants declared that the frequency 
of candidemia caused by Candida species other than Candida 
albicans was lower than 10%; the actual proportion reported 
in most studies varies from 40% to 74%8.  Additionally, more 
than 90% of the physicians were not aware of the increase of 
C. glabrata incidence that has been documented in some medical 
centers in Brazil7,14,15. As shown in Table 1, misunderstanding 
of the epidemiology of candidemia was particularly common 
among the ICU physicians.
In addition, ICU and ID physicians also had different views 
on the clinical use of antifungal susceptibility testing. Data 
obtained in this study showed that the ICU physicians were less 
aware of the importance of identifying Candida at the species 
level for predicting its susceptibility to antifungal drugs. For 
instance, C. lusitaniae is known to be amphotericin B-resistant, 
and both C. guilliermondii and C. parapsilosis have decreased 
in vitro susceptibility to echinocandins9. ICU physicians seemed 
to be particularly uninformed regarding these associations. 
In contrast, the frequency of compulsory requests for in vitro 
susceptibility tests was higher for the ICU physicians than for the 
ID physicians. This ﬁ nding could be the result of sampling bias 
because many of the ICU physicians were working in the same 
hospital, and the requests for susceptibility tests could reﬂ ect 
institutional protocols. Moreover, many ICU physicians reported 
a willingness to use voriconazole for candidemic patients in 
which ﬂ uconazole had failed, which demonstrates a lack of 
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knowledge regarding cross-resistance in the triazole class. This 
lack of knowledge may be attributable to ICU physicians being 
less familiar with the IDSA’s guidelines. 
Several medical societies, including the IDSA, recognize 
the importance of antifungal drug treatment for all patients 
with candidemia3. This recommendation is justiﬁ ed by the high 
mortality associated with candidemia (at least 50%) and by the 
potential for metastatic complications in patients not treated with 
antifungal drugs2. However, 21.4% of the participants in this 
study appeared to not systematically treat candidemia, and most 
of these participants were ICU specialists (34.4%; p=0.008). It 
should be noted that no clinical or laboratory data are available to 
allow clinicians to safely select patients with transient episodes 
of candidemia that would not require treatment. 
Fluconazole was the ﬁ rst-choice antifungal treatment for 
most physicians in this study, most likely because of their 
longstanding familiarity with fluconazole’s safety profile 
and dosing. However, many physicians referenced the use of 
ﬁ xed doses of ﬂ uconazole rather than guiding therapy based 
on body weight; additionally, the administration of loading 
doses was frequently regarded as unimportant3, with ICU and 
ID physicians registering similar opinions. Fluconazole was 
also preferred in situations in which the IDSA’s guidelines 
recommend other therapeutic options.
One of the most striking ﬁ ndings of this study was the limited 
knowledge demonstrated by participants on the echinocandin 
class of antifungal drugs. Only 45.8% of ID physicians and 25% 
of ICU specialists reported using echinocandins as a ﬁ rst-line 
treatment for unstable patients with candidemia (p=0.154). 
This is in frank contrast to the latest guidelines for treating 
patients with candidemia3; in such a scenario, echinocandins 
are considered ﬁ rst-choice treatments. The limited availability 
of this antifungal class in the Brazilian market at the time of the 
survey in addition to the scarcity of resources at public hospitals, 
which comprised a large number of our sampling sites, may 
explain the apparently limited knowledge that the physicians 
had about this drug.
Removal of central venous catheters has been recommended 
in the IDSA’s guidelines as an adjunct measure in the treatment 
of patients with candidemia3 despite the controversy regarding 
this subject10. In this study, the ICU physicians endorsed a more 
aggressive approach regarding catheter management: 93.8% 
would remove catheters promptly, in comparison to 70.8% of 
ID physicians (p=0.030). As expected, these proportions were 
reduced to ~50% when long-term catheters were considered.
Another striking finding of this study was the limited 
frequency in which eye examination was performed in 
patients with candidemia, particularly by ICU physicians 
(~45%). Although fungal endophthalmitis is an uncommon 
condition, it may lead to blindness and requires speciﬁ c and 
prolonged treatment once the diagnosis is made. Therefore, eye 
examination is recommended for all patients with candidemia11. 
In one investigation in Brazil, the frequency of eye examination 
in patients with candidemia was as low as 7.6%12, which 
indicates the importance of educating healthcare professionals 
on this subject. 
Consistent with this study’s ﬁ ndings, Eggimann et al.13 
observed that many differences in management approaches 
between ICU and ID physicians also exist in Switzerland13.
The present study reveals the need to better educate physicians 
in Brazil regarding invasive Candida infection, which is an 
important and aggressive infection with a high mortality if not 
correctly identiﬁ ed and treated. Nevertheless, the appropriate 
management of this disease depends on increasing the drug 
options available in our country and encouraging global coverage 
in private and public hospitals, thereby improving health care.
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